Literature DB >> 28443143

Does androgen-deprivation therapy for prostate cancer increase the risk for thromboembolic disease?

Jehonathan H Pinthus1, Wilhelmina C Duivenvoorden1.   

Abstract

Entities:  

Year:  2017        PMID： 28443143      PMCID： PMC5403687          DOI： 10.5489/cuaj.4394

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  11 in total

1.  Androgen deprivation and thromboembolic events in men with prostate cancer.

Authors:  Behfar Ehdaie; Coral L Atoria; Amit Gupta; Andrew Feifer; William T Lowrance; Michael J Morris; Peter T Scardino; James A Eastham; Elena B Elkin
Journal:  Cancer       Date:  2011-11-09       Impact factor: 6.860

2.  The effect of parenteral estrogen versus orchiectomy on blood coagulation and fibrinolysis in prostatic cancer patients.

Authors:  J Aro; R Haapiainen; V Rasi; S Rannikko; O Alfthan
Journal:  Eur Urol       Date:  1990       Impact factor: 20.096

3.  Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?

Authors:  Alok A Khorana; Daniel Yannicelli; Keith R McCrae; Dejan Milentijevic; Concetta Crivera; Winnie W Nelson; Jeffrey R Schein
Journal:  Thromb Res       Date:  2016-07-26       Impact factor: 3.944

4.  Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.

Authors:  Adi J Klil-Drori; Hui Yin; Vicky Tagalakis; Armen Aprikian; Laurent Azoulay
Journal:  Eur Urol       Date:  2015-06-29       Impact factor: 20.096

Review 5.  The role of diethylstilbestrol in the treatment of prostate cancer.

Authors:  S B Malkowicz
Journal:  Urology       Date:  2001-08       Impact factor: 2.649

6.  Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.

Authors:  Jim C Hu; Stephen B Williams; A James O'Malley; Matthew R Smith; Paul L Nguyen; Nancy L Keating
Journal:  Eur Urol       Date:  2012-02-01       Impact factor: 20.096

7.  Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.

Authors:  Sean O'Farrell; Karin Sandström; Hans Garmo; Pär Stattin; Lars Holmberg; Jan Adolfsson; Mieke Van Hemelrijck
Journal:  BJU Int       Date:  2015-11-19       Impact factor: 5.588

8.  Thromboelastography identifies hypercoagulablilty and predicts thromboembolic complications in patients with prostate cancer.

Authors:  Mazen Toukh; D Robert Siemens; Angela Black; Sylvia Robb; Michael Leveridge; Charles H Graham; Maha Othman
Journal:  Thromb Res       Date:  2013-10-12       Impact factor: 3.944

Review 9.  Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

Authors:  Marcello Di Nisio; Ettore Porreca; Matteo Candeloro; Michele De Tursi; Ilaria Russi; Anne Ws Rutjes
Journal:  Cochrane Database Syst Rev       Date:  2016-12-01

Review 10.  Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis.

Authors:  Freesia Horsted; Joe West; Matthew J Grainge
Journal:  PLoS Med       Date:  2012-07-31       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.